Pharma Pulse: Foundayo’s FDA Approval and the Strategic Risk of Pharmacy Data Consolidation

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I’m your host, and let’s get into today’s headlines.

First, Eli Lilly’s Foundayo has become the first new molecular entity approved under the FDA’s National Priority Voucher pilot, clearing the agency in a record 50 days. As the only GLP-1 weight-loss pill that can be taken any time without food or water restrictions, Foundayo is positioned to significantly boost patient adherence. It will be available through LillyDirect starting April 6th, with home delivery options aimed at increasing therapy access.

Next, a new commentary warns of a “quiet consolidation” as pharmacy technology moves toward a few dominant platforms. While these systems offer integrated workflows, they also aggregate vast amounts of independent pharmacy data for private equity and corporate monetization. Experts urge owners to treat technology contracts as strategic business deals to maintain control over their data’s long-term value.

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.
You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.